Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Humanized mouse model of Rasmussen’s encephalitis supports the immune-mediated hypothesis
Hania Kebir, … , Alexandre Prat, Elie Haddad
Hania Kebir, … , Alexandre Prat, Elie Haddad
Published April 9, 2018
Citation Information: J Clin Invest. 2018;128(5):2000-2009. https://doi.org/10.1172/JCI97098.
View: Text | PDF
Research Article Immunology Neuroscience

Humanized mouse model of Rasmussen’s encephalitis supports the immune-mediated hypothesis

  • Text
  • PDF
Abstract

Rasmussen’s encephalitis (RE) is a chronic inflammatory brain disorder that causes frequent seizures and unilateral hemispheric atrophy with progressive neurological deficits. Hemispherectomy remains the only treatment that leads to seizure freedom for this refractory epileptic syndrome. The absence of an animal model of disease has been a major obstacle hampering the development of effective therapies. Here, we describe an experimental mouse model that shares several clinical and pathological features with the human disease. Immunodeficient mice injected with peripheral blood mononuclear cells from RE patients and monitored by video electroencephalography developed severe seizures of cortical origin and showed intense astrogliosis and accumulation of human IFN-γ– and granzyme B–expressing T lymphocytes in the brain compared with mice injected with immune cells from control subjects. We also provide evidence for the efficacy of α4 integrin blockade, an approved therapy for the treatment of multiple sclerosis and Crohn’s disease, in reducing inflammatory markers associated with RE in the CNS. This model holds promise as a valuable tool for understanding the pathology of RE and for developing patient-tailored experimental therapeutics.

Authors

Hania Kebir, Lionel Carmant, François Fontaine, Kathie Béland, Ciprian M. Bosoi, Nathalie T. Sanon, Jorge I. Alvarez, Sébastien Desgent, Camille L. Pittet, David Hébert, Marie-Josée Langlois, Rose-Marie Rébillard, Dang K. Nguyen, Cécile Cieuta-Walti, Gregory L. Holmes, Howard P. Goodkin, John R. Mytinger, Mary B. Connolly, Alexandre Prat, Elie Haddad

×

Figure 3

Neuropathology in RE-NSG animals.

Options: View larger image (or click on image) Download as PowerPoint
Neuropathology in RE-NSG animals.
(A) Confocal photomicrograph showing G...
(A) Confocal photomicrograph showing GFAP (red) and hCD45+ (green) in the CNS of control-NSG and RE-NSG mice 5 weeks after transfer. Scale bar: 30 μm; insets ×3 magnification. (B) Quantification of hCD45+ cells and staining intensity for GFAP in the CNS of control-NSG and RE-NSG mice. Data represent the mean ± SEM of 10 or more fields from 6 sections obtained from 3 animals per group. ***P < 0.001, by unpaired, 2-tailed Student’s t test. (C) Immunohistoperoxidase staining for APP in the hippocampal gyrus of control-NSG and RE-NSG mice 6 weeks after transfer. Arrowheads indicate APP+ neuronal cells. Scale bar: 30 μm. (D) Quantification of cell death marker TUNEL in the CNS of control-NSG and RE-NSG mice 6 weeks after transfer. Data are expressed as the mean ± SEM of 10 to 20 fields from 6 sections obtained from 2 animals per group. *P < 0.05, by unpaired, 2-tailed Student’s t test. (E) Immunofluorescence staining for hCD45 (green), cleaved caspase-3 (Cas-3, red), and NeuN (upper panels, white) or IB4 (lower panels, white) in the brains of RE-NSG mice. DAPI (blue) was used for nuclear staining. Images are representative of 7 fields from 3 sections obtained from 3 RE-NSG mice. Scale bars: 20 μm. The two upper left inset frames show ×1.33 magnification of the dashed boxed area. All other insets are magnified ×2.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts